Mirati Therapeutics Gross Profit 2006-2021 | MRTX

Mirati Therapeutics annual/quarterly gross profit history and growth rate from 2006 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Mirati Therapeutics gross profit for the quarter ending June 30, 2021 was $M, a NAN% increase year-over-year.
  • Mirati Therapeutics gross profit for the twelve months ending June 30, 2021 was $0.013B, a 637.28% increase year-over-year.
  • Mirati Therapeutics annual gross profit for 2020 was $0.013B, a 301.74% increase from 2019.
  • Mirati Therapeutics annual gross profit for 2019 was $0.003B, a 74.2% decline from 2018.
  • Mirati Therapeutics annual gross profit for 2018 was $0.013B, a INF% increase from 2017.
Mirati Therapeutics Annual Gross Profit
(Millions of US $)
2020 $13
2019 $3
2018 $13
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $3
2010 $2
2009 $3
2008 $28
2007 $15
2006 $14
2005 $6
Mirati Therapeutics Quarterly Gross Profit
(Millions of US $)
2021-06-30
2021-03-31
2020-12-31 $2
2020-09-30 $11
2020-06-30
2020-03-31 $0
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $3
2018-09-30
2018-06-30
2018-03-31 $9
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $0
2011-09-30 $0
2011-06-30 $1
2011-03-31 $1
2010-12-31 $1
2010-09-30 $1
2010-06-30 $0
2010-03-31 $0
2009-12-31 $1
2009-09-30 $0
2009-06-30 $0
2009-03-31 $1
2008-12-31 $14
2008-09-30 $6
2008-06-30 $4
2008-03-31 $4
2007-12-31 $5
2007-09-30 $3
2007-06-30 $3
2007-03-31 $3
2006-12-31 $7
2006-09-30 $8
2006-06-30 $2
2006-03-31 $-3
2005-12-31 $1
2005-09-30 $1
2005-06-30 $2
2005-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.588B $0.013B
Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29